XML 21 R11.htm IDEA: XBRL DOCUMENT
v3.23.2

GOODWILL AND OTHER INTANGIBLE ASSETS | 6 Months Ended
--- | ---
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND OTHER INTANGIBLE ASSETS | GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Changes in the carrying amount of goodwill for the six-month period ended June 30, 2023 were as follows:
Dollars in thousands | Codman Specialty Surgical |  | Tissue Technologies |  | Total
Goodwill at December 31, 2022 | $ | 656,219 |  |  | $ | 382,662 |  |  | $ | 1,038,881 |
SIA Acquisition Working Capital Adjustment | — |  |  | (382) |  |  | (382) |
Foreign currency translation | 3,015 |  |  | 1,759 |  |  | 4,774 |
Goodwill at June 30, 2023 | $ | 659,234 |  |  | $ | 384,039 |  |  | $ | 1,043,273 |
The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative analysis. In the second quarter of 2023, due to the voluntary recall of Primatrix®, Surgimend®, Revize™, and TissueMend™ as well as the associated drop in the Company's stock price in Q2, the Company elected to perform a quantitative analysis for its Tissue Technologies reporting unit. The quantitative test estimates the fair value of the reporting unit using a discounted cash flow model, which incorporates significant estimates and assumptions made by management which, by their nature, are characterized by uncertainty. The quantitative test utilized a long-term growth rate of 2% and a discount rate of 10%. The Company determined, after performing the quantitative analysis, that the fair value of the goodwill of the reporting unit was not less than the carrying amount, with more than 20% headroom. Other Intangible Assets The components of the Company’s identifiable intangible assets were as follows:
| June 30, 2023
Dollars in thousands | Weighted Average Life |  | Cost |  | Accumulated Amortization |  | Net
Completed technology | 18 years |  | $ | 1,211,660 |  |  | $ | (408,428) |  |  | $ | 803,232 |
Customer relationships | 12 years |  | $ | 193,550 |  |  | $ | (148,103) |  |  | $ | 45,447 |
Trademarks/brand names | 28 years |  | $ | 97,950 |  |  | $ | (36,700) |  |  | $ | 61,250 |
Codman tradename | Indefinite |  | $ | 169,279 |  |  | $ | — |  |  | $ | 169,279 |
Supplier relationships | 30 years |  | $ | 30,211 |  |  | $ | (17,659) |  |  | $ | 12,552 |
All other | 11 years |  | $ | 6,064 |  |  | $ | (4,228) |  |  | $ | 1,836 |
|  |  | $ | 1,708,714 |  |  | $ | (615,118) |  |  | $ | 1,093,596 |
| December 31, 2022
Dollars in thousands | Weighted Average Life |  | Cost |  | Accumulated Amortization |  | Net
Completed technology | 18 years |  | $ | 1,204,325 |  |  | $ | (370,968) |  |  | $ | 833,357 |
Customer relationships | 12 years |  | 193,081 |  |  | (144,040) |  |  | 49,041 |
Trademarks/brand names | 28 years |  | 97,265 |  |  | (34,674) |  |  | 62,591 |
Codman tradename | Indefinite |  | 166,693 |  |  | — |  |  | 166,693 |
Supplier relationships | 30 years |  | 30,211 |  |  | (17,170) |  |  | 13,041 |
All other | 11 years |  | 5,957 |  |  | (4,071) |  |  | 1,886 |
|  |  | $ | 1,697,532 |  |  | $ | (570,923) |  |  | $ | 1,126,609 |
Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of goods sold) is expected to be approximately $41.4 million for the remainder of 2023, $82.2 million in 2024, $82.2 million in 2025, $82.0 million in 2026, $80.0 million in 2027, $78.5 million in 2028 and $477.1 million thereafter. The Company periodically performs testing for impairment on certain long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the second quarter of 2023, due to the voluntary recall of Primatrix®, Surgimend®, Revize™, and TissueMend™, the Company elected to perform impairment testing on certain definite lived intangibles. The impairment testing estimates the fair value of the intangibles using an undiscounted cash flow model. The Company determined, after performing the impairment testing, that the fair value of the intangibles was not less that the carrying amount.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration